Noncardiac Death Risk Limits Cardiovascular Prognosis in Type 2 Infarction

Prognostic Heterogeneity in Myocardial Injury and Infarction

The widespread use of high-sensitivity cardiac troponin assays has unmasked a diverse population of patients with myocardial injury who do not fit the classic criteria for a Type 1 myocardial infarction [1]. While aggressive secondary prevention remains the standard for atherothrombotic events, the long-term trajectory for patients with troponin elevations from other causes is less defined [2, 3]. This ambiguity presents a clinical challenge: how does the underlying etiology of myocardial injury, as classified by the Universal Definition, affect a patient's risk of future cardiovascular events versus death from other causes? A new large-scale meta-analysis addresses this question by examining the competing risks of cardiovascular and noncardiovascular mortality across the full spectrum of myocardial injury and infarction [4, 5].

Meta-Analysis of Universal Definition Categories

To clarify these long-term outcomes, researchers conducted a systematic review and meta-analysis of studies published between January 1, 2007, and July 1, 2025. The analysis included 17 prospective studies from 9 cohorts across 9 countries, all of which measured cardiac troponin for suspected acute coronary syndrome, adjudicated diagnoses using the Universal Definition, and reported cause-specific mortality at a minimum of one year. This rigorous selection process yielded a large and diverse patient population for analysis.

The final cohort comprised 120,734 patients (median age 61.0 years; 45.8% women), with individual patient-level data available for 8 of the 9 cohorts. The primary outcome was major adverse cardiovascular events (MACE), defined as a composite of recurrent myocardial infarction or cardiovascular death. The secondary outcome was noncardiovascular death. To provide a clinically accurate risk assessment, the investigators calculated subdistribution hazard ratios, a statistical method specifically designed to account for competing risks. This approach is crucial in this context because it estimates the likelihood of a cardiovascular event while acknowledging that a patient might first succumb to a non-cardiac cause, thereby preventing an overestimation of the true MACE risk.

Data were synthesized using random-effects models, a statistical technique that accommodates expected variation between different study populations. By employing this robust methodology, the analysis offers a more nuanced understanding of the distinct risk profiles associated with each category of myocardial injury and infarction, moving beyond simple event rates to consider the interplay between cardiovascular and noncardiovascular mortality.

Incidence and Ischemic Risk Across Etiologies

The analysis first established the prevalence of different myocardial injury classifications within the large patient cohort. Type 1 myocardial infarction was the most common diagnosis, occurring in 9.4% of patients (n = 11,298), followed by acute myocardial injury in 4.9% (n = 5,864), chronic myocardial injury in 4.7% (n = 5,625), and Type 2 myocardial infarction in 3.0% (n = 3,609). These figures confirm that a substantial portion of patients with elevated troponins do not have a primary coronary occlusion, highlighting the need for precise risk stratification.

The findings confirmed that any form of myocardial injury or infarction significantly increases the risk of future cardiovascular events compared to patients with no injury. For Type 1 myocardial infarction, the MACE rate was 55.2 per 1,000 patient-years, corresponding to a subdistribution hazard ratio of 4.82 (95% CI: 3.55-6.57). Patients with Type 2 myocardial infarction had a similarly high MACE rate of 51.7 per 1,000 patient-years, but their risk profile was complicated by a much higher rate of noncardiovascular death. Their MACE risk remained substantial, with a subdistribution hazard ratio of 3.36 (95% CI: 2.92-3.86).

Patients with myocardial injury without infarction also faced elevated cardiovascular risk. The acute myocardial injury group had a MACE rate of 47.1 per 1,000 patient-years and a subdistribution hazard ratio of 3.24 (95% CI: 2.41-4.36). For those with chronic myocardial injury, the MACE rate was 44.9 per 1,000 patient-years, with a subdistribution hazard ratio of 3.03 (95% CI: 2.53-3.62). These data demonstrate that while all four conditions confer a roughly three- to five-fold increase in the risk of a future cardiovascular event, the absolute rates of competing non-cardiac mortality differ dramatically among them, directly impacting overall prognosis.

The Competing Burden of Noncardiovascular Mortality

A central finding of the study is the profound impact of noncardiovascular death on the prognosis of patients with Type 2 myocardial infarction and acute myocardial injury. While the MACE rates for Type 1 and Type 2 infarction appeared similar, their mortality sources were starkly different. The noncardiovascular death rate for Type 2 myocardial infarction was 60.1 per 1,000 patient-years, more than double the rate of 25.7 per 1,000 patient-years seen in Type 1 patients. This suggests that for many patients with Type 2 events, the underlying condition driving the supply-demand mismatch (e.g., sepsis, anemia, tachyarrhythmia) is a greater threat to survival than recurrent ischemic events.

This burden of non-cardiac death was even more pronounced in patients with acute myocardial injury, who had the highest rate across all groups at 67.0 per 1,000 patient-years. In contrast, the rate for chronic myocardial injury was 46.9 per 1,000 patient-years. For the practicing clinician, these results underscore a critical point: while cardiovascular risk must be addressed in all patients with elevated troponins, management of Type 2 myocardial infarction and acute myocardial injury must prioritize the diagnosis and treatment of the underlying non-cardiac pathology. The study indicates that in these populations, the substantial competing risk of noncardiovascular death may temper the absolute benefit of conventional cardiovascular secondary prevention strategies alone.

References

1. Zhou S, Li W, Xiang Q, et al. Optimal anti-platelet therapy for older patients with acute coronary syndrome: a network meta-analysis of randomized trials comprising 59,284 older patients.. Journal of thrombosis and thrombolysis. 2024. doi:10.1007/s11239-023-02875-x

2. Group TSR. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine. 2015. doi:10.1056/nejmoa1511939

3. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004. doi:10.1161/01.cir.0000133317.49796.0e

4. Wang Y, Fuerte-Hortigon A, Chetty S, et al. Types and Rates of Major Adverse Cardiovascular Events in Antithrombotic Trials: A Systematic Review and Meta-Analysis.. The Canadian journal of cardiology. 2025. doi:10.1016/j.cjca.2025.08.358

5. Mehran R, Rao SV, Bhatt DL, et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials. Circulation. 2011. doi:10.1161/circulationaha.110.009449